Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.China Pharma Receives SFDA Approval For Rosuvastatin
China Pharma has received official approval from China’ State Food and Drug Administration (SFDA) to enter phase-I and phase-II clinical trials, to test the efficacy of cholesterol-lowering drug,
China Pharma has received official approval from China’ State Food and Drug Administration (SFDA) to enter phase-I and phase-II clinical trials, to test the efficacy of cholesterol-lowering drug,
Enzon has initiated the phase-II trial for PEG-SN38 (EZN-2208), its novel proprietary cancer compound. The trial is open at multiple centers in US to patients diagnosed with metastatic
Biomodels has announced that its customized research program allowed ActoGeniX to get FDA approval for phase 1b clinical trials of AGO13, in cancer patients with oral mucositis. The
NeurogesX and Astellas Pharma have entered into an exclusive distribution, marketing and license agreement for the commercialization of Qutenza, in the European Economic Area (EEA). The agreement closely
Biogen has enrolled its first patient in phase III, randomized, double-blind, placebo-controlled trial, designed to evaluate the efficacy and safety of PEGylated interferon beta-1a (BIIB017) in patients with
Eurand has reported that FDA has extended the June 2009 user fee goal date for the New Drug Application for Zenpep, by three months. Zenpep is a proprietary
BioLineRx has reported new results confirming its GABA enhanced BL-1020 drug’ MOA. BL-1020 is an orally available antipsychotic for the treatment of schizophrenia. BL-1020 has recently completed a
Cannabis Science (Cannabis) is all set to file patent for two of its key innovations, processing systems and drug delivery systems. Cannabis’ management has authorized expenditures for patents, the innovations will be
Hospira has announced that the US District Court for New Jersey, has granted summary judgment of non-infringement in Hospira’ favour, with regard to Sanofi Aventis’ chemotherapy medication, Eloxatin. The
GTC Biotherapeutics (GTC) has signed agreements with LFB (a wholly-owned subsidiary of LFB S.A) to provide a total of $12.3 million of cash proceeds to GTC, with an option